Quick Answer
Two founders, same city, same week, both raising fifty lakh rupees from angels. One closes in nine days on iSAFE notes and gets back to shipping product. The other spends eleven weeks negotiating a CCPS round with a full shareholders’ agreement, and walks away with patient institutional style capital and a governance framework that will carry her to Series A. Neither founder is wrong. They were answering different questions. The instrument you choose for early money decides three things: how fast you close, who carries the valuation risk, and what rights travel with the cheque. India offers three main answers, straight equity, compulsorily convertible preference shares, and the iSAFE note, and this article compares them the way you actually experience them: speed, dilution, control, and what happens when things go sideways.
- Straight equity prices everything today and suits trust money; CCPS price today with downside protection and governance, and are the institutional standard; iSAFEs defer pricing for speed and suit angel and bridge money, provided you model the conversion stack before it models you. The instruments are not rivals but tools in sequence, and the best cap tables use each where it is strongest. Whatever you choose, the Companies Act ceremony and, for foreign money, FEMA compliance are not optional garnish; they are the difference between capital and complication.

Straight equity: simple, final, and unforgiving
Straight equity means the investor subscribes to ordinary shares at an agreed price per share, through the private placement process we map in our seed stage legal stack article. The moment money moves, ownership is fixed forever. No conversion mechanics, no preference stack, one class of shares, a cap table a child could read. The simplicity has a price, and it is the valuation. Pricing equity at the idea stage is astrology with a spreadsheet: price too low and you have sold a large slice of your company for pocket change; price too high and your next round becomes a down round with all its signalling damage. Equity also makes the investor a full shareholder immediately, with the statutory rights that follow, so choose co-owners, not just cheques. Straight equity suits money from people pricing you on trust rather than models, family, close angels, and small rounds where everyone wants maximum simplicity and nobody wants preference gymnastics.
CCPS: the institutional standard, for reasons that make sense
Compulsorily convertible preference shares are the workhorse of Indian venture investing. The investor holds preference shares that must convert into equity, at a ratio fixed by formula, on defined triggers, typically the next round or an exit horizon, and until conversion they carry preference features: liquidation preference, so the investor gets their money back before founders in a sale or winding up, anti dilution adjustments if a later round prices lower, and the contractual rights package of a shareholders’ agreement, board seat or observer, reserved matters, information rights. For foreign investors, CCPS have an additional virtue: they are treated as equity under FEMA, making them the compliant instrument for offshore venture money. The costs are time and complexity. A CCPS round means a negotiated SSA and SHA, an articles amendment, valuation reports, and the full closing choreography, weeks of work and real legal fees. The preference stack also plants seeds that grow at exit: a modest 1x non participating liquidation preference is market standard and fair; participating preferences and ratchets at seed stage are the red flags we catalogue in our term sheet article. CCPS suit meaningful rounds, a crore and above as a loose intuition, with investors who are pricing the company now and staying for the journey.
iSAFE: India’s answer to the valuation question nobody can answer
The SAFE, born at Y Combinator, asks a clever question: why price the company today at all? Take the money now, and give the investor the right to receive shares when a priced round happens later, usually with a discount or a valuation cap as reward for early risk. The Indian adaptation, popularised as the iSAFE, wraps this idea in Companies Act clothing: since Indian law does not recognise the American SAFE as an instrument, the iSAFE is implemented as CCPS issued now with conversion terms keyed to the future round, an agreement to deliver future equity dressed in preference share form, compliant with Sections 42, 55, and 62. The experience is speed. Documentation runs a fraction of a full CCPS round, negotiation compresses because valuation, the hardest conversation, is deferred, and rolling closes let you bank angel cheques one by one instead of herding everyone to a single closing. Founders keep a clean cap table until conversion and typically give minimal governance rights in the interim. The traps are the deferred conversations. Valuation caps are valuations in disguise: a five crore cap on an iSAFE is a statement about your worth, and stacking multiple iSAFEs at different caps builds a dilution surprise that detonates at the priced round, when every note converts at once and founders discover their real ownership. Model the conversion waterfall before you sign the third note, not after. Also mind the legal reality that an iSAFE holder in India is typically already a shareholder of a preference class, not a mere contract counterparty as in the US, so statutory formalities still apply in full. iSAFEs suit fast angel rounds, bridge money between rounds, and any situation where deferring valuation is honestly better than guessing it.
The decision, framed as three questions
Can you defend a valuation today? If yes, price it, CCPS for institutional money, straight equity for trust money. If no, defer it with an iSAFE and a sensible cap. How much governance is the cheque buying? Institutional cheques expect SHA rights, angel cheques should not demand Series A packages, and iSAFEs should travel light. And what does your next investor want to find? A tidy stack, one instrument per layer, modelled conversion, articles matching agreements, is itself an asset; a drawer of inconsistent notes is a diligence tax. A composite example makes it concrete. A Pune healthtech raises twenty five lakhs from three angels on iSAFEs, cap of eight crore, in two weeks. A year later, a fund leads a three crore seed on CCPS at a twelve crore pre money: the iSAFEs convert at their cap, the angels earn their early risk premium, the SHA and articles are built once, properly, at the priced round. Each instrument did the one job it is best at, in sequence.
Can AI help choose and manage the instrument?
For the modelling, emphatically yes. AI tools can build the conversion waterfall across stacked notes, simulate founder dilution under different caps, discounts, and next round sizes, translate an SSA’s preference clauses into plain English, and flag where an investor’s draft deviates from market norms. The dilution surprises that ambush founders at priced rounds are exactly the arithmetic AI never gets tired of. The limits are legal and real: whether a conversion formula works under the Companies Act, whether FEMA pricing rules bite a foreign investor’s note, whether your articles actually permit what the instrument promises, these are practitioner questions, and AI trained largely on American startup content will confidently import US SAFE assumptions that are simply wrong in India. Model with the machine; paper with a qualified human who has closed Indian rounds.
When to Review This
- Straight equity prices everything today and suits trust money; CCPS price today with downside protection and governance, and are the institutional standard; iSAFEs defer pricing for speed and suit angel and bridge money, provided you model the conversion stack before it models you. The instruments are not rivals but tools in sequence, and the best cap tables use each where it is strongest. Whatever you choose, the Companies Act ceremony and, for foreign money, FEMA compliance are not optional garnish; they are the difference between capital and complication.
Disclaimer
This article is for general information only and is not legal advice. Instrument choice depends on your specific facts, so take professional advice before acting.

